HCP
HAE icon

Hexagon Capital Partners’s Haemonetics HAE Stock Holding History

Hexagon Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-129
Closed -$8.2K – 765
2025
Q1 		$8.2K Sell
129
-6
-4% -$408 ﹤0.01% 1031
2024
Q4 		$10.5K Buy
135
+1
+0.7% +$80 ﹤0.01% 996
2024
Q3 		$10.8K Buy
134
+58
+76% +$4.69K ﹤0.01% 895
2024
Q2 		$6.29K Buy
76
+22
+41% +$1.94K ﹤0.01% 965
2024
Q1 		$4.61K Buy
54
+50
+1,250% +$3.92K ﹤0.01% 1011
2023
Q4 		$343 Sell
4
-69
-95% -$5.96K ﹤0.01% 1324
2023
Q3 		$6.54K Sell
73
-104
-59% -$9.29K ﹤0.01% 847
2023
Q2 		$15.1K Buy
177
+54
+44% +$4.57K ﹤0.01% 638
2023
Q1 		$10.2K Sell
123
-30
-20% -$2.43K ﹤0.01% 724
2022
Q4 		$12K Buy
153
+16
+12% +$1.29K ﹤0.01% 675
2022
Q3 		$10K Buy
+137
New +$9.84K ﹤0.01% 771

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.82B AUM 7.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Hexagon Capital Partners's HAE Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 129 shares — an estimated $8.2K sold.

Hexagon Capital Partners first reported a position in HAE in Q3 2022 and held it in 11 quarters. The position peaked at $15.1K in Q2 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 129 Haemonetics shares in Q2 2025, an estimated $8.2K.
  • Hexagon Capital Partners first reported a position in Haemonetics in Q3 2022 and held it in 11 quarters.
  • Hexagon Capital Partners's Haemonetics position peaked at $15.1K in Q2 2023.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.